Browse by category

Laekna and Eli Lilly to develop ActRIIA antibody for muscle-preserving weight loss in obesity

Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...

Lilly and UK government announce £279 million collaboration to tackle population health challenges including obesity

Eli Lilly and Company has announced a strategic collaboration with the UK’s Department of Health and Social Care (DHSC), Department for...

Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity

Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with...

WHO issues warning on falsified medicines as Lilly warns patients about counterfeit and compounded medicines

The World Health Organization (WHO) has issued a medical product alert on falsified semaglutides, the type of medicines that are used for...

Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity

Eli Lilly and Company has announced positive topline results from the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...

Lilly's Zepbound (tirzepatide) achieved total mean weight loss of 26.0% from baseline to 88 weeks

Detailed results from SURMOUNT-4 have shown Zepbound (tirzepatide) injection achieved superior mean percent change in body weight...

Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide

Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...

Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks

Phase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...

SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweight

Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli...

Obesity-related brain changes can be reversed after bariatric surgery

10 minutes ago

Verge Genomics reveals VRG201 as its candidate for long-term weight management and metabolic homeostasis

21 minutes ago

Structure Therapeutics selects oral small molecule amylin receptor agonist ACCG-2671 for obesity treatment

49 minutes ago

Weekly Digest